Find Business Directory

The Recover offers reporting on trending news topics about addiction and mental health. A team of experienced journalists write non-bias news about major health news issues. The medication is not a pill; instead, it is delivered intravenously over the course of 60-hours, which means it would be given in the setting of a hospital or licensed clinic, rather than the patients home. Clinical studies for the treatment showed terrific results. Not only were the numbers outstanding but the rapid relief that follows the treatment shocked the patients involved. According to the reports, the team performed a double-blind placebo that included multiple women that experienced moderate to severe postpartum depression. Each woman reported immediate improvements in their symptoms within 24 hours; the improvements were still present after 30 days. “This is for postpartum depression, but it is a step in understanding how we treat depression more broadly,” explained Dr. Samantha Meltzer-Brody, director of the perinatal psychiatry program at the University of North Carolina at Chapel Hill and the principal academic investigator in the brexanolone trials. “We have had the same treatments for depression for 30 years. There’s an enormous need for new, novel ways to treat depression, and to treat it quickly.”

Home » Link Detail

Addiction and Mental Health News
Title:	Addiction and Mental Health News
URL:	https://www.therecover.com/
Description:	The Recover offers reporting on trending news topics about addiction and mental health. A team of experienced journalists write non-bias news about major health news issues. The medication is not a pill; instead, it is delivered intravenously over the course of 60-hours, which means it would be given in the setting of a hospital or licensed clinic, rather than the patients home. Clinical studies for the treatment showed terrific results. Not only were the numbers outstanding but the rapid relief that follows the treatment shocked the patients involved. According to the reports, the team performed a double-blind placebo that included multiple women that experienced moderate to severe postpartum depression. Each woman reported immediate improvements in their symptoms within 24 hours; the improvements were still present after 30 days. “This is for postpartum depression, but it is a step in understanding how we treat depression more broadly,” explained Dr. Samantha Meltzer-Brody, director of the perinatal psychiatry program at the University of North Carolina at Chapel Hill and the principal academic investigator in the brexanolone trials. “We have had the same treatments for depression for 30 years. There’s an enormous need for new, novel ways to treat depression, and to treat it quickly.”